Bio-Path Holdings, Inc. (BPTH)
OTCMKTS
· Delayed Price · Currency is USD
0.1410
+0.0010 (0.71%)
Apr 25, 2025, 2:05 PM EDT
Bio-Path Holdings Employees
Bio-Path Holdings had 10 employees as of December 31, 2024. The number of employees did not change compared to the previous year.
Employees
10
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$989,400
Market Cap
1.20M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Endo Inc. | 3,116 |
| Glass House Brands | 374 |
| Elite Pharmaceuticals | 64 |
| Northwest Biotherapeutics | 25 |
| CytoDyn | 9 |
| American Oncology Network | 1,914 |
| Silence Therapeutics | 116 |
| Longduoduo Company | 49 |
Bio-Path Holdings News
- 4 weeks ago - Bio-Path GAAP EPS of -$4.12 - Seeking Alpha
- 4 weeks ago - Bio-Path Holdings Reports Full Year 2024 Financial Results - GlobeNewsWire
- 5 weeks ago - Bio-Path Holdings Announces Pre-Clinical Results Signaling Increased Potential for BP1001-A as Treatment for Obesity in Type 2 Diabetes Patients - GlobeNewsWire
- 2 months ago - ARMISTICE CAPITAL, LLC Acquires Significant Stake in Bio-Path Holdings Inc - GuruFocus
- 2 months ago - Bio-Path Holdings Provides Key Clinical Updates - GlobeNewsWire
- 2 months ago - Bio-Path Holdings Provides Update from Phase 1/1b Clinical Trial of BP1002 for Treatment of Refractory/Relapsed Acute Myeloid Leukemia - GlobeNewsWire
- 3 months ago - Bio-Path Holdings Provides 2025 Clinical and Operational Update - GlobeNewsWire
- 4 months ago - Bio-Path Holdings Announces Preclinical Testing of BP1001-A as Potential Treatment for Obesity in Type 2 Diabetes Patients Enhances Insulin Sensitivity - GlobeNewsWire